Literature DB >> 31654722

Impaired metabolism of kynurenine and its metabolites in CSF of parkinson's disease.

Kazuhiro Iwaoka1, Chigumi Otsuka2, Tetsuya Maeda3, Kanako Yamahara4, Kanako Kato5, Kenta Takahashi6, Kai Takahashi7, Yasuo Terayama8.   

Abstract

AIM: The kynurenine (KYN) pathway plays an important role in degrading molecules responsible for oxidative stress in the central nervous system (CNS), but can also have neurotoxic effects. Both 3-hydroxykynurenine (3-HK) and quinolinic acid are neurotoxic metabolites produced from this pathway. In Parkinson's disease (PD), oxidative stress is suspected to represent a key pathogenic mechanism. This study aimed to investigate the function of the KYN pathway and interactions between oxidative stress and neuroinflammation in PD.
METHODS: Participants comprised 20 patients with PD and 13 controls. Cerebrospinal fluid (CSF) levels of KYN and 3-HK were measured using high-performance liquid chromatography coupled with an electrochemical detector. CSF levels of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, and interferon (IFN)-γ were measured with an enzyme-linked immunosorbent assay, and results were statistically compared between PD patients and controls.
RESULTS: Median CSF levels of KYN and 3-HK were 49.0 nM and 4.25 nM in PD and 30.5 nM and 1.55 nM in controls, respectively, showing significantly higher levels in PD (p < 0.05). CSF levels of measured cytokines showed that TNF-α and IL-1β were significantly higher in PD patients than in controls. No positive correlation between 3-HK and TNF-α was seen in PD.
CONCLUSION: Dysfunction of the KYN pathway may induce oxidative stress in the CNS in PD, and may also induce cytokine-mediated neuroinflammation. Functional amelioration of the KYN pathway may facilitate modification of neurodegenerative processes in PD.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Kynurenine pathway; Neuroinflammation; Oxidative stress; Parkinson’s disease

Mesh:

Substances:

Year:  2019        PMID: 31654722     DOI: 10.1016/j.neulet.2019.134576

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  12 in total

Review 1.  Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders.

Authors:  Michael Y Bai; David B Lovejoy; Gilles J Guillemin; Rouba Kozak; Trevor W Stone; Maju Mathew Koola
Journal:  Complex Psychiatry       Date:  2021-02-08

Review 2.  Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinson's Disease.

Authors:  Milan Zimmermann; Kathrin Brockmann
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

3.  Genotypic-Phenotypic Analysis, Metabolic Profiling and Clinical Correlations in Parkinson's Disease Patients from Tamil Nadu Population, India.

Authors:  Dhivya Venkatesan; Mahalaxmi Iyer; Robert Wilson S; Arul Narayanasamy; Siva Kamalakannan; Abilash Valsala Gopalakrishnan; Balachandar Vellingiri
Journal:  J Mol Neurosci       Date:  2022-06-08       Impact factor: 2.866

4.  Peripheral and central kynurenine pathway abnormalities in major depression.

Authors:  Elisabeth R Paul; Lilly Schwieler; Sophie Erhardt; Sandra Boda; Ada Trepci; Robin Kämpe; Anna Asratian; Lovisa Holm; Adam Yngve; Robert Dantzer; Markus Heilig; J Paul Hamilton; Martin Samuelsson
Journal:  Brain Behav Immun       Date:  2022-01-06       Impact factor: 19.227

Review 5.  Advantages of brain penetrating inhibitors of kynurenine-3-monooxygenase for treatment of neurodegenerative diseases.

Authors:  Shaowei Zhang; Mary E W Collier; Derren J Heyes; Flaviano Giorgini; Nigel S Scrutton
Journal:  Arch Biochem Biophys       Date:  2020-12-01       Impact factor: 4.013

Review 6.  Parkinson's Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?

Authors:  Vidar Gundersen
Journal:  Front Neurosci       Date:  2021-02-25       Impact factor: 4.677

Review 7.  Hypoxia and the Kynurenine Pathway: Implications and Therapeutic Prospects in Alzheimer's Disease.

Authors:  Oluyomi Stephen Adeyemi; Oluwakemi Josephine Awakan; Lawrence Boluwatife Afolabi; Damilare Emmanuel Rotimi; Elizabeth Oluwayemi; Chiagoziem A Otuechere; Omodele Ibraheem; Tobiloba Chritiana Elebiyo; Omokolade Alejolowo; Afolake T Arowolo
Journal:  Oxid Med Cell Longev       Date:  2021-11-10       Impact factor: 6.543

8.  Differentiation of viral and autoimmune central nervous system inflammation by kynurenine pathway.

Authors:  Yi Luo; Nora Möhn; Thomas Skripuletz; Makbule Senel; Hayrettin Tumani; Frank Peßler; Kurt-Wolfram Sühs; Martin Stangel
Journal:  Ann Clin Transl Neurol       Date:  2021-10-08       Impact factor: 4.511

Review 9.  Update on CSF Biomarkers in Parkinson's Disease.

Authors:  Eun Hae Kwon; Sabrina Tennagels; Ralf Gold; Klaus Gerwert; Léon Beyer; Lars Tönges
Journal:  Biomolecules       Date:  2022-02-18

10.  Cerebrospinal Fluid TNF-α and Orexin in Patients With Parkinson's Disease and Rapid Eye Movement Sleep Behavior Disorder.

Authors:  Yuan Yuan; Yimeng Zhang; Yueyang Cheng; Yue Hou; Zhaoyang Huang; Jinghong Ma; Ning Li; Shuqin Zhan
Journal:  Front Neurol       Date:  2022-02-18       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.